Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a, Multicenter, First-in-human, Open-label Clinical Trial Evaluating MDX2001 Monotherapy in Patients With Advanced Solid Tumors

NCT06239194 is registered in ClinicalTrials.gov with ModeX Therapeutics, An OPKO Health Company as lead sponsor.

NCT NCT06239194
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06239194 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a, Multicenter, First-in-human, Open-label Clinical Trial Evaluating MDX2001 Monotherapy in Patients With Advanced Solid Tumors
Lead sponsor
ModeX Therapeutics, An OPKO Health Company
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 12, 2024
Completion date
February 28, 2029
Enrollment
285 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer, breast cancer, cervical cancer, colon cancer, endometrial cancer, esophageal cancer, gastric cancer, gastroesophageal cancer, head and neck cancer, hepatocellular cancer, non-small cell lung cancer, pancreatic cancer, prostate cancer, rectal cancer, renal cancer, thyroid cancer